[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 589
Citations 0
Comment & Response
March 24/31, 2015

Treatment to Prevent Hepatitis B Virus Reactivation in Patients With Lymphoma Receiving Chemotherapy

Author Affiliations
  • 1Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania
JAMA. 2015;313(12):1269-1270. doi:10.1001/jama.2015.1438

To the Editor Dr Huang and colleagues1 showed the benefits of using a drug with a better resistance profile (entecavir) in preventing hepatitis B virus (HBV) reactivation in patients with lymphoma receiving chemotherapy who were seropositive for the hepatitis B surface antigen. Only 6.6% (n = 4) of patients experienced HBV reactivation in the entecavir group.

First Page Preview View Large
First page PDF preview
First page PDF preview
×